Latest & greatest articles for doxycycline

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on doxycycline or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on doxycycline and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for doxycycline

1. A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BL

A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BL A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids

2017 NIHR HTA programme

2. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis

The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2014 PROSPERO

3. Oral Doxycycline in the Management of Acne Vulgaris: Current Perspectives on Clinical Use and Recent Findings with a New Double-scored Small Tablet Formulation (PubMed)

Oral Doxycycline in the Management of Acne Vulgaris: Current Perspectives on Clinical Use and Recent Findings with a New Double-scored Small Tablet Formulation Oral antibiotics have been used for the treatment of acne vulgaris for six decades. Among dermatologists, tetracyclines represent at least three-fourths of the oral antibiotics prescribed in clinical practice. Unlike other specialties, antibiotic use in dermatology is predominantly for the treatment of noninfectious disorders (...) , such as acne vulgaris and rosacea, which usually involves prolonged therapy over several weeks to months as compared to short courses used to treat cutaneous infections. At the present time, doxycycline and minocycline are the most commonly prescribed tetracyclines in dermatology, used primarily for treatment of acne vulgaris with a long overall favorable track record of effectiveness and safety. Although both are commonly used, doxycycline may be chosen by clinicians more readily as there is a lower risk

Full Text available with Trip Pro

2015 The Journal of clinical and aesthetic dermatology

4. Subantimicrobial-dose doxycycline and cytokine-chemokine levels in gingival crevicular fluid. (PubMed)

Subantimicrobial-dose doxycycline and cytokine-chemokine levels in gingival crevicular fluid. The present randomized, double-masked, placebo-controlled, parallel-arm study examines the impact of adjunctive subantimicrobial-dose doxycycline (SDD) on the local inflammatory response through cytokine and chemokine levels in gingival crevicular fluid (GCF) samples from patients with chronic periodontitis.Forty-six patients with chronic periodontitis received scaling and root planing with or without

2011 Journal of periodontology

5. A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. (PubMed)

A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Azithromycin prophylaxis has been shown to reduce COPD exacerbations but there is poor evidence for other antibiotics. We compared exacerbation rates in COPD patients with a history of frequent exacerbations (at least three moderate or severe COPD exacerbations (...) in the past two years) during a 12-week treatment course and over a subsequent 48-week follow up period.292 patients were randomised to one of three treatments for 12 weeks: roxithromycin 300 mg daily and doxycycline 100 mg daily (n = 101); roxithromycin 300 mg daily (n = 97); or matching placebos (n = 94). There were no differences in the annualised moderate and severe exacerbation rates after treatment with roxithromycin/doxycycline (2.83 (95 % CI 2.37-3.40)) or roxithromycin only (2.69 (2.26-3.21

Full Text available with Trip Pro

2015 Journal of negative results in biomedicine

6. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. (PubMed)

Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. There is a paucity of treatment options for severe acne vulgaris aside from oral isotretinoin. This randomized, vehicle-controlled, multicenter, double-blind study evaluated the efficacy and safety of combination therapy using adapalene 0.1%-benzoyl peroxide 2.5% (A/BPO) fixed (...) -dose combination gel with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris. A total of 459 participants were randomized in a 1:1 ratio to receive oral doxycycline hyclate 100 mg once daily and either A/BPO or vehicle once daily for 12 weeks. Efficacy in the A/BPO with doxycycline group was demonstrated as early as week 2 compared with the vehicle arm for total, inflammatory, and noninflammatory lesions (all P < .005). At week 12, this combination was superior to vehicle

2010 Cutis; cutaneous medicine for the practitioner

7. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. (PubMed)

Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. Community-acquired pneumonia (CAP) affects 5-10 million adults annually in the United States with approximately 1.1 million hospitalizations. Current guidelines recommend fluoroquinolones as monotherapy for treatment of CAP in general medical wards and doxycycline monotherapy for outpatient therapy only. Fluoroquinolones are expensive and development of bacterial resistance to them has become a concern. Therefore, we (...) studied whether doxycycline is as efficacious as levofloxacin in treatment of CAP in general medical wards.In this prospective double-blinded trial, non-pregnant adults with clinical and radiological evidence of pneumonia requiring hospitalization were enrolled. Patients who were septic, hypoxic requiring intubations, nursing home residents, diagnosed with severe hepatic or renal dysfunction, recently hospitalized or immunocompromised were excluded from the study. Subjects were randomly assigned

2010 Journal of clinical pharmacy and therapeutics

8. Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne

Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne (POWER) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01474590 Recruitment Status : Completed

2011 Clinical Trials

9. Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial. (PubMed)

Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial. Several guidelines advocate the same treatment approaches for both early disseminated Lyme borreliosis, manifested as multiple erythema migrans (EM), and early localized Lyme borreliosis, manifested as solitary EM.Oral doxycycline (100 mg q12h) was compared on a non-inferiority premise with intravenous ceftriaxone (2 g q24h) for 14 days in 200 adult (...) doxycycline and 6/88 (6.8%) multiple EM patients prescribed ceftriaxone showed incomplete response manifested predominantly as post-Lyme symptoms (1.9% difference, upper limit of 95% CI 5.1%). The upper limit of 95% CI for the difference in proportion of patients with incomplete response between doxycycline and ceftriaxone groups did not exceed the predetermined non-inferiority margin of 10%. The frequency of non-specific symptoms in patients was similar to that in controls.The 14 day oral doxycycline

Full Text available with Trip Pro

2018 Journal of Antimicrobial Chemotherapy

10. Efficacy of doxycycline in the treatment of syphilis. (PubMed)

Efficacy of doxycycline in the treatment of syphilis. Doxycycline is an alternative antibiotic drug for the treatment of syphilis, but data on its efficacy, especially data on its efficacy against late latent syphilis, are limited. A retrospective study was conducted to evaluate the effectiveness of doxycycline for the treatment of patients with different stages of syphilis. Patients who received doxycycline treatment between June 2011 and June 2014 were involved. The serological response (...) to doxycycline was defined as either a negative toluidine red unheated serum test (TRUST) result or a ≥4-fold decrease in titer at 12 months following the treatment. Univariate and multivariate logistic regression analyses were performed to identify factors associated with the serological response. During the study period, a total of 163 syphilis patients were treated with doxycycline, and 118 patients completed doxycycline treatment and the 12-month follow-up. Among the 118 patients, the serological

Full Text available with Trip Pro

2016 Antimicrobial Agents and Chemotherapy

11. The efficacy of host response modulation using low dose of doxycycline or anti-inflammatory drugs on periodontal disease therapy: a systematic review

The efficacy of host response modulation using low dose of doxycycline or anti-inflammatory drugs on periodontal disease therapy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2016 PROSPERO

12. Effects of doxycycline on clinical, microbiological and immunological parameters in well-controlled diabetes type- 2 patients with periodontal disease. A randomized controlled clinical trial. (PubMed)

Effects of doxycycline on clinical, microbiological and immunological parameters in well-controlled diabetes type- 2 patients with periodontal disease. A randomized controlled clinical trial. To evaluate the clinical, microbiological and immunological effects of systemic doxycycline as an adjunct to scaling and root planing (SRP) in chronic periodontitis patients with well-controlled type 2 diabetes.Sixty-six patients compliant to oral hygiene (Hygiene Index <20%) allocated to either a test (...) (systemic doxycycline for 21 days) or a control (placebo) group participated in the present randomized controlled trial (RCT). Clinical assessments were recorded at baseline, 3 and 6 months after therapy and included clinical attachment level (CAL), set as the primary outcome of the study, probing pocket depth (PPD), recession (RE) and bleeding on probing (BOP). At the same time points, counts of 15 subgingival species were evaluated by "checkerboard" DNA-DNA hybridization, gingival crevicular fluid

2014 Journal of clinical periodontology

13. Subantimicrobial-Dose Doxycycline (SDD) Periodontal therapy reduces serum biomarkers of systemic inflammation and can increase high-density lipoprotein

Subantimicrobial-Dose Doxycycline (SDD) Periodontal therapy reduces serum biomarkers of systemic inflammation and can increase high-density lipoprotein UTCAT856, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Subantimicrobial-Dose Doxycycline (SDD) Periodontal Therapy Reduces Serum Biomarkers Of Systemic Inflammation And Can Increase High-Density Lipoprotein Clinical Question In post-menopausal women with chronic (...) periodontitis does a systemic dose of Doxycycline in comparison to placebo increase high-density lipoprotein (HDL) levels? Clinical Bottom Line In post-menopausal women with chronic periodontitis Subantimicrobial-Dose Doxycycline Periodontal therapy reduces serum biomarkers of systemic inflammation and among women more than five years post-menopausal, the SDD regimen elevated their level of high-density lipoprotein (HDL) cholesterol. (See Comments on the CAT below) Best Evidence (you may view more info

2011 UTHSCSA Dental School CAT Library

14. Efficacy of short-term adjunctive subantimicrobial dose doxycycline in diabetic patients--randomized study. (PubMed)

Efficacy of short-term adjunctive subantimicrobial dose doxycycline in diabetic patients--randomized study. To investigate the effectiveness of short-term adjunctive subantimicrobial dose doxycycline (SDD) treatment in patients with diabetes mellitus type 2 and chronic periodontitis (CP).Thirty-four patients with CP and type 2 diabetes mellitus were included in the placebo-controlled, double-blind study. After scaling and root planing (SRP), patients were randomly assigned to two groups

2012 Oral diseases

15. Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream

Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01345526 Recruitment Status : Unknown Verified April 2011 by Universitätsmedizin Mannheim. Recruitment status was: Recruiting First Posted : May 2, 2011 Last Update Posted : May

2011 Clinical Trials

16. A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: A protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER (PubMed)

A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: A protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER Bullous pemphigoid (BP) is the most common autoimmune blistering disease in older people, and is associated with significant morbidity and mortality. Oral corticosteroids are usually effective but the side-effects are thought to contribute (...) to the high morbidity and mortality rate. Treatment with oral tetracyclines may be effective but high-quality, randomized controlled trials (RCTs) are needed to confirm this.To compare the effectiveness and safety of two strategies for treating BP.This is a two-arm, parallel group, 52-week RCT comparing doxycycline with prednisolone for initial treatment of BP. Dose is fixed for the initial 6 weeks of treatment (doxycycline 200 mg daily; prednisolone 0.5 mg kg(-1) daily), after which it can be adjusted

2015 The British journal of dermatology

17. Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea

Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing

2009 Clinical Trials

18. Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness

Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness DATE: 27 November 2012 CONTEXT AND POLICY ISSUES The potential use of anthrax as a biological terrorist attack has

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. Doxycycline monohydrate - Rosacea treatment

Doxycycline monohydrate - Rosacea treatment Common Drug Review CDEC Meeting — January 16, 2013; CDEC Reconsideration — March 20, 2013 Notice of CDEC Final Recommendation — March 27, 2013 Page 1 of 4 © 2013 CADTH FINAL CDEC RECOMMENDATION DOXYCYCLINE MONOHYDRATE (Apprilon – Galderma Canada Inc.) Indication: Inflammatory Rosacea Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that 40 mg doxycycline modified- release capsules not be listed. Reason for the Recommendation (...) : The Committee considered the comparative clinical benefit of 40 mg doxycycline modified- release (MR) capsules to be uncertain due to limitations in the design and analysis of the single randomized controlled trial (RCT) (ROSE-401) that compared 40 mg doxycycline MR capsules with 100 mg doxycycline immediate-release (IR) capsules. Background: Doxycycline monohydrate has a Health Canada indication for the treatment of inflammatory lesions (papules and pustules) of rosacea in adult patients. Doxycycline has

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

20. Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol. (PubMed)

Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol. Rectal infection with Chlamydia trachomatis is one of the most common bacterial sexually transmissible infections among men who have sex with men (MSM) with diagnosis rates continuing to rise. Current treatment guidelines recommend either azithromycin 1 g single dose (...) or doxycycline 100 mg twice daily for 7 days. However, there are increasing concerns about treatment failure with azithromycin. We are conducting the first randomised controlled trial (RCT) to compare treatment efficacy of azithromycin versus doxycycline for the treatment of rectal chlamydia in MSM.The Rectal Treatment Study will recruit 700 MSM attending Australian sexual health clinics for the treatment of rectal chlamydia. Participants will be asked to provide rectal swabs and will be randomised to either

Full Text available with Trip Pro

2017 BMC Infectious Diseases